ALGN, SYK And ABT, Pushing Health Services Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 14 points (0.1%) at 16,515 as of Thursday, April 24, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,645 issues advancing vs. 1,332 declining with 182 unchanged.

The Health Services industry currently sits up 0.2% versus the S&P 500, which is up 0.3%. A company within the industry that fell today was Thermo Fisher Scientific ( TMO), up 3.0%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Align Technology ( ALGN) is one of the companies pushing the Health Services industry lower today. As of noon trading, Align Technology is down $2.34 (-4.5%) to $50.11 on heavy volume. Thus far, 1.8 million shares of Align Technology exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $48.56-$52.80 after having opened the day at $52.25 as compared to the previous trading day's close of $52.45.

Align Technology, Inc. operates as a medical device company primarily in the United States and internationally. Align Technology has a market cap of $4.2 billion and is part of the health care sector. Shares are down 8.2% year-to-date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Align Technology a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Align Technology as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Align Technology Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Stryker Corporation ( SYK) is down $0.54 (-0.7%) to $77.85 on heavy volume. Thus far, 2.1 million shares of Stryker Corporation exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $76.89-$80.78 after having opened the day at $80.50 as compared to the previous trading day's close of $78.39.

Stryker Corporation, together with its subsidiaries, operates as a medical technology company. The company operates in three segments: Reconstructive, MedSurg, and Neurotechnology and Spine. Stryker Corporation has a market cap of $29.8 billion and is part of the health care sector. Shares are up 4.3% year-to-date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Stryker Corporation a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Stryker Corporation as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Stryker Corporation Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Abbott Laboratories ( ABT) is down $0.21 (-0.5%) to $38.39 on light volume. Thus far, 2.3 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 8.7 million shares. The stock has ranged in price between $38.10-$38.65 after having opened the day at $38.65 as compared to the previous trading day's close of $38.60.

Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $59.6 billion and is part of the health care sector. Shares are up 0.7% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its expanding profit margins and increase in stock price during the past year. However, as a counter to these strengths, we find that net income has been generally deteriorating over time. Get the full Abbott Laboratories Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Stocks Sputter as U.S. 10-Year Yields Test 3% Amid Commodity-Led Inflation Spike

Stocks Sputter as U.S. 10-Year Yields Test 3% Amid Commodity-Led Inflation Spike

Global Stocks Slip as Rising Yields, Tech Weakness, Unsettle Markets

Global Stocks Slip as Rising Yields, Tech Weakness, Unsettle Markets

European and U.S. Stocks Called Higher as Earnings Season Hits Full-Speed

European and U.S. Stocks Called Higher as Earnings Season Hits Full-Speed

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors